PARP1 catalytic domain mutations drive high-level resistance to saruparib while preserving DNA damage response vulnerabilities
Matthew R. Jordan, Jessica Lynn Kersey, Joy Garrett…·John J. Turchi
This study identifies PARP1 catalytic domain mutations as a mechanism of high-level resistance to saruparib in BRCA1-deficient breast cancer cells, while retaining DDR vulnerabilities.